Clinical observation of Wenyun Decoction in treating obese polycystic ovary syndrome
- Conditions
- polycystic ovary syndrome
- Registration Number
- ITMCTR2100004474
- Lead Sponsor
- onghua Hospital Shanghai University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
1. Meet the diagnostic criteria of western medicine for obese polycystic ovary syndrome;
2. Comply with the syndrome differentiation standard of deficiency of kidney yang and mutual congestion of phlegm and blood stasis in TCM;
3. The course of the disease is within 2 years;
4. Patients (gender) between 18 and 35 years old;
5. Patients who have signed an informed consent form.
6. If the subject has used weight loss drugs (such as orlistat, liraglutide, etc.), anti-androgen drugs (Diane-35, spironolactone, etc.), ovulation induction within 1 month before being included in the study Drugs (clomiphene, etc.) can be included in this study after a 3-month drug wash-out period.
1. Patients with mental illness and severe diseases such as cardiovascular, cerebrovascular, liver, and hematopoietic system;
2. Allergic constitution, or pregnant or lactating women;
3. Patients who participated in other clinical trials within the past 3 months;
4. People with mental illness;
5. Those with contraindications to metformin hydrochloride tablets.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Therapeutic effect of TCM syndromes;Visceral fat area;
- Secondary Outcome Measures
Name Time Method Subcutaneous fat area;Menstrual condition;laboratory inspection;